지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2022.6
- 수록면
- 1 - 10 (10page)
이용수
초록· 키워드
오류제보하기
Purpose: Apurinic/apyrimidinic endonuclease 1 (APE1) is a key enzyme involved in the base excision repair pathway. It also has redox activity and maintains various transcription factors in an active reduced state. APE1 may be associated with chemoresistance. In the present study, we first investigated the expression level of APE1 protein and its correlation with oncologic outcomes of oxaliplatin-based chemotherapy in patients with stage III colon cancer. Further, we investigated the effects of human APE1 siRNA on the sensitivity of oxaliplatin in SNU-C2A colon cancer cells.
Methods: Tissue specimens from tumor and normal colon of 33 patients with stage III colon cancer were obtained from 2006 to 2009. The patients received at least eight cycles of oxaliplatin-based chemotherapy. APE1 expression was analyzed by immunohistochemistry and Western blotting using a cultured SNU-C2A cell line. Cell viability and apoptosis were determined by Cell Counting Kit-8 and caspase-3 cleavage using Western blotting.
Results: All the colon cancer tissues showed APE1 staining in the nucleus, whereas all the normal colon tissues were negative for APE1 staining in the cytoplasm. The group with a higher expression of APE1 demonstrated poorer prognosis than the group with low expression (P=0.026 for overall survival and P=0.021 for disease-free survival). Treatment with oxaliplatin resulted in a dose-dependent increase in APE1 expression in SNU-C2A cells. APE1 siRNA significantly enhanced oxaliplatin-induced growth inhibition, and also increased oxaliplatin-induced apoptosis in SNU-C2A cells.
Conclusion: APE1 could be considered a prognostic factor in colon cancer patients treated with oxaliplatin-based chemotherapy.
Methods: Tissue specimens from tumor and normal colon of 33 patients with stage III colon cancer were obtained from 2006 to 2009. The patients received at least eight cycles of oxaliplatin-based chemotherapy. APE1 expression was analyzed by immunohistochemistry and Western blotting using a cultured SNU-C2A cell line. Cell viability and apoptosis were determined by Cell Counting Kit-8 and caspase-3 cleavage using Western blotting.
Results: All the colon cancer tissues showed APE1 staining in the nucleus, whereas all the normal colon tissues were negative for APE1 staining in the cytoplasm. The group with a higher expression of APE1 demonstrated poorer prognosis than the group with low expression (P=0.026 for overall survival and P=0.021 for disease-free survival). Treatment with oxaliplatin resulted in a dose-dependent increase in APE1 expression in SNU-C2A cells. APE1 siRNA significantly enhanced oxaliplatin-induced growth inhibition, and also increased oxaliplatin-induced apoptosis in SNU-C2A cells.
Conclusion: APE1 could be considered a prognostic factor in colon cancer patients treated with oxaliplatin-based chemotherapy.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Altered Secretory Activity of APE1/Ref-1 D148E Variants Identified in Human Patients With Bladder Cancer
International Neurourology Journal
2016 .01
-
APE1/Ref-1 as a Serological Biomarker for the Detection of Bladder Cancer
Cancer Research and Treatment
2015 .01
-
Role of APE1/Ref-1 in hydrogen peroxide-induced apoptosis in human renal HK-2 cells
Kidney Research and Clinical Practice
2024 .03
-
Dynamic Regulation of APE1/Ref-1 as a Therapeutic Target Protein
전남의대학술지
2016 .01
-
Effect of Adjuvant Chemotherapy on Stage II Colon Cancer: Analysis of Korean National Data
Cancer Research and Treatment
2018 .01
-
Adjuvant chemotherapy in patients with stage II colon cancer
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2018 .12
-
Evaluation of the antinociceptive activities of natural propolis extract derived from stingless bee Trigona thoracica in mice
The Korean Journal of Pain
2024 .04
-
Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer
Annals of Surgical Treatment and Research
2018 .04
-
Is Adjuvant Chemotherapy Beneficial for Oldest-old (Aged 80 Years or Older) Patients with Stage II Colon Cancer?
대한외과학회 학술대회 초록집
2020 .11
-
The Prognosis and Recurrence Pattern of Right- and Left-Sided Colon Cancer in Stage II, Stage III, and Liver Metastasis After Curative Resection
Annals of Coloproctology
2021 .10
-
Acrosorium polyneurum Extract Inhibits the LPS-Induced Inflammatory Response by Impairing the MAPK and NF-κB Pathways
JOURNAL OF BACTERIOLOGY AND VIROLOGY
2016 .12
-
Adjuvant Chemotherapy and Prognostic Factors in Stage II Colon Cancer - Izmir Oncology Group Study
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Pathologic Factors Associated with Prognosis after Adjuvant Chemotherapy in Stage II/III Microsatellite-Unstable Colorectal Cancers
Journal of Pathology and Translational Medicine
2015 .01
-
Refractive Predictability between Standard and Total Keratometry during the Femtosecond Laser-Assisted Cataract Surgery with Monofocal Intraocular Lens with Enhanced Intermediate Function
Korean Journal of Ophthalmology
2024 .02
-
The Effect of Adjuvant Chemotherapy for Stage IIa(T3N0) Colon Cancer
대한임상종양학회 학술대회지
2016 .02
-
Is radical surgery for clinical stage I right-sided colon cancer relevant? A retrospective review
Annals of Surgical Treatment and Research
2020 .03
-
Prognostic Factors Affecting Disease-Free Survival and Overall Survival in T4 Colon Cancer
Annals of Coloproctology
2021 .08
-
Capecitabine Plus Oxaliplatin Combination Therapy for Basal Cell Carcinoma
Annals of Dermatology
2019 .01
-
Oncologic outcomes of early adjuvant chemotherapy initiation in patients with stage Ⅲ colon cancer
Annals of Surgical Treatment and Research
2015 .08
-
Survival analysis for colon subsite and rectal cancers : Experience from a single surgeon
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2015 .12
이 논문의 저자 정보
최근 본 자료
댓글(0)
0